Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

210

Citations

15

References

2002

Year

Maurie Markman, James B. Hall, Daniel L. Spitz, Sheldon Weiner, Linda F. Carson, Linda Van Le, Mark E. Baker

Journal of Clinical Oncology

Abstract

Weekly paclitaxel (80 mg/m(2)) is generally well tolerated and is an active second-line regimen against ovarian cancer that has demonstrated resistance to platinum/paclitaxel delivered on an every-3-week schedule.

References

	Year	Citations
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William P. McGuire, William J. Hoskins, Mark F. Brady, New England Journal of Medicine	1996	2.9K
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling, PubMed Tumor BiologyChemoprevention StrategyMedicineAntiangiogenic SchedulingTumor Growth	2000	1.6K
Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms William P. McGuire Annals of Internal Medicine Chemoprevention StrategyPathologyGynecologyPharmacotherapyMetronomic Chemotherapy	1989	1.1K
Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results M. Piccart JNCI Journal of the National Cancer Institute	2000	1K
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink, Kenneth D. Swenerton, Journal of Clinical Oncology	1994	640
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J.T. Thigpen, John A. Blessing, Harrison Ball, Journal of Clinical Oncology	1994	389
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. G.J.S. Rustin, Ann E. Nelstrop, Patrick McClean, Journal of Clinical Oncology	1996	377
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Eric K. Rowinsky, Ross C. Donehower, RJ Jones, PubMed Cell DeathCytoskeletonDiterpenoid Plant ProductTumor BiologyHematological Malignancy	1988	375
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. Maurie Markman, Eric K. Rowinsky, Thomas B. Hakes, Journal of Clinical Oncology	1992	313
Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines Narima M. Lopes, Earl G. Adams, Thomas W. Pitts, Cancer Chemotherapy and Pharmacology Cell DivisionMedicineCell DeathCell CultureCell Proliferation	1993	274

Page 1